{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:09:39Z","timestamp":1779296979919,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.7759\/cureus.94583","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T19:09:19Z","timestamp":1760468959000},"source":"Crossref","is-referenced-by-count":1,"title":["A Triple Threat: Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis, Myocarditis, and Adrenal Insufficiency in a Patient With Metastatic Melanoma"],"prefix":"10.7759","author":[{"given":"Aamir Mohamed","family":"Nur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus","volume":"87","author":"Kani ER","year":"2025","unstructured":"Kani ER, Karaviti E, Karaviti D, et al.. Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus. Endocrine. 2025, 87:875-90. 10.1007\/s12020-024-04050-5","journal-title":"Endocrine"},{"key":"ref2","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette JMK","year":"2019","unstructured":"de Filette JMK, Pen JJ, Decoster L. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019, 181:363-74.","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2661","article-title":"Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis","volume":"8","author":"Lu J","year":"2019","unstructured":"Lu J, Li L, Lan Y, Liang Y, Meng H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis. Cancer Med. 2019, 8:7503-15. 10.1002\/cam4.2661","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Zulma Cardona","year":"2023","unstructured":"Zulma Cardona, Jeffrey A, Sunandana Chandra, Huang W. Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol. 2023, 14:10.3389\/fendo.2023.1157805","journal-title":"Front Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2017.8.1.5","article-title":"Understanding and managing immune-related adverse events associated with immune checkpoint inhibitors in patients with advanced melanoma","volume":"8","author":"Weinstein A","year":"2017","unstructured":"Weinstein A, Gordon RA, Kasler MK, et al.. Understanding and managing immune-related adverse events associated with immune checkpoint inhibitors in patients with advanced melanoma. J Adv Pract Oncol. 2017, 8:58-72. 10.6004\/jadpro.2017.8.1.5","journal-title":"J Adv Pract Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt Z","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020, 200:131-40. 10.1111\/cei.13424","journal-title":"Clin Exp Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra S","year":"2018","unstructured":"Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018, 23:879-86. 10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 67:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.. Incidence of endocrine dysfunction following the use of immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JBAG","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou SA","year":"2021","unstructured":"Paschou SA, Stefanaki K, Psaltopoulou T, et al.. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021, 6:100011. 10.1016\/j.esmoop.2020.100011","journal-title":"ESMO Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95. 10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/421714-a-triple-threat-immune-checkpoint-inhibitor-induced-diabetic-ketoacidosis-myocarditis-and-adrenal-insufficiency-in-a-patient-with-metastatic-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T19:09:20Z","timestamp":1760468960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/421714-a-triple-threat-immune-checkpoint-inhibitor-induced-diabetic-ketoacidosis-myocarditis-and-adrenal-insufficiency-in-a-patient-with-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.94583","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}